Skip to content

KPV

PeptidespeptideEarly stage

Availability Not yet prescribable · sold for research use only

What it is

KPV is a tripeptide, three amino acids long, made of the tail end of alpha-melanocyte-stimulating hormone. The parent hormone drives pigmentation and appetite; this fragment keeps the anti-inflammatory activity and drops the rest. It is one of the few peptides sold in oral form, because its small size lets some of it survive digestion.

Why people take it

Interest clusters around inflammation people can feel: irritable bowel symptoms, inflammatory bowel disease, and skin conditions such as eczema and slow-healing wounds. The pitch is a targeted calming signal rather than a systemic immunosuppressant, and the oral and topical routes make it an easier first peptide for people who do not want injections.

How it's delivered

Some clinics advertise oral, topical and injectable KPV. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound KPV acetate for an individual patient's prescription under conditions that include: a single-ingredient oral or topical product made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing KPV; its Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records. Injectable KPV is outside it. As with any unapproved compound, the pharmacy behind the product determines what is actually in it.

Where the evidence stands

The preclinical case is coherent. KPV reduces inflammation in animal models of colitis, appears to work through melanocortin-independent routes rather than by activating pigmentation receptors, and reaches the colon in usable form. Published work on the isolated tripeptide's anti-inflammatory effect goes back to the early 2000s. What does not exist is a controlled human trial. FDA removed KPV from Category 2 after its nomination was withdrawn; FDA's safety concerns remain. Anyone framing KPV as proven for gut disease is ahead of the record.

Estimated cost

  • No approved product and no verified reference price
  • Not covered by insurance

Who offers it

We don't list providers for KPV. There is no approved product, and we haven't verified any provider against the conditions of HHS's draft October 2026 interim compounding policy. Anything sold online as a research chemical is outside that policy.

Go deeper

The compound page, KPV in the Peptide Explorer, is the depth layer. The lane guide, Peptides for Immune Health, covers immune-modulating peptides and where medical context changes the calculus.

Longevity.io is for educational purposes only and is not medical advice. Whether KPV belongs in a plan is a conversation for a clinician who knows the whole picture, active gut or skin disease included. Confirm eligibility, product source, and pricing directly with any provider.

Your Longevity Blueprint

Build your starting plan.

A few short questions, about two minutes. The Blueprint recommends where to start and explains why.

Build my Blueprint